VIENNA, Va. (BUSINESS WIRE) $CVM #Multikine CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinom.
Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.